Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to $141.7 million.

  • Silence Therapeutics' Shares Outstanding (Weighted Average) fell 22.76% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 22.76%. This contributed to the annual value of $138.8 million for FY2024, which is 0.46% up from last year.
  • Silence Therapeutics' Shares Outstanding (Weighted Average) amounted to $141.7 million in Q3 2025, which was up 0.00% from $141.7 million recorded in Q2 2025.
  • Silence Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $183.5 million during Q3 2024, with a 5-year trough of $113.3 million in Q4 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $141.7 million (2025), whereas its average is $153.7 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first rose by 21.91% in 2023, then decreased by 22.76% in 2025.
  • Over the past 4 years, Silence Therapeutics' Shares Outstanding (Weighted Average) (MRQ) stood at $113.3 million in 2022, then grew by 21.91% to $138.1 million in 2023, then increased by 0.46% to $138.8 million in 2024, then grew by 2.13% to $141.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $141.7 million for Q3 2025, versus $141.7 million for Q2 2025 and $141.7 million for Q1 2025.